Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2007
04/17/2007CA2407759C Substituted phenylacetamides and their use as glucokinase activators
04/17/2007CA2387915C Direct compression polymer tablet core
04/17/2007CA2386799C Fused cycloheptane and fused azacycloheptane compounds and their as integrin receptor antagonists
04/17/2007CA2374635C Sulfuric acid mono-[3-({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester
04/17/2007CA2371645C Naphtalene or heterocyclically substituted benzimidazoles as parp inhibitors
04/17/2007CA2358885C Pyrazolecarboxylic acid derivatives, their preparation, pharmaceutical compositions containing them
04/17/2007CA2350073C Ccr5 modulators
04/17/2007CA2348725C Vitamin d analogues
04/17/2007CA2341690C Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
04/17/2007CA2337051C Methods for increasing vascularization and promoting wound healing
04/17/2007CA2321267C Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent
04/17/2007CA2320731C Antibiotics in dry dosage forms for the treatment of shallow ulcers of the oral mucosa
04/17/2007CA2318381C Novel tricyclic compounds, preparation method and pharmaceutical compositions containing same
04/17/2007CA2308721C Radio-opaque polymer biomaterials
04/17/2007CA2299300C Arylpyridazinones as prostaglandin endoperoxide h synthase bisoynthesis inhibitors
04/17/2007CA2295792C A crystalline dibenzothiazepine derivative and its use as an antipsychotic agent
04/17/2007CA2290549C Anti-helicobacter pylori pharmaceutical composition
04/17/2007CA2283648C Polymeric carrier
04/17/2007CA2280960C Oxirancarboxylic acids for the treatment of diabetes
04/17/2007CA2277151C Synthesis of acyclic nucleoside derivatives
04/17/2007CA2272882C Ketone derivatives and their medical applications
04/17/2007CA2271085C Indolecarboxylic compounds and their use as pharmaceutical compounds
04/17/2007CA2261310C Novel adsorbent
04/17/2007CA2250586C Meta-substituted phenylene sulphonamide derivatives
04/17/2007CA2231332C Bacterial delivery system
04/17/2007CA2226214C Antifungal agent, compound therefor, process for producing the same, and method for using the same
04/17/2007CA2203412C Bisarylcarbinol cinnamic acids as inhibitors of leukotriene biosynthesis
04/17/2007CA2202775C Method for treating anxiety
04/17/2007CA2196197C Retinoic acid x-receptor ligands
04/17/2007CA2190765C Novel potent inducers of terminal differentiation and methods of use thereof
04/17/2007CA2190357C Chewable flubendazole tablets for companion animals
04/17/2007CA2184175C Isolated, tyrosinase derived peptides and uses thereof
04/17/2007CA2182417C Oral dosage form containing colestipol as a carrier and acidic active substances and a process for producing the same
04/17/2007CA2163793C Novel antiviral agents
04/17/2007CA2158630C Dosage forms containing thioctic acid or solid salts of thioctic acid with improved release and bioavailability
04/17/2007CA2141589C Antiretroviral enantiomeric nucleotide analogs
04/17/2007CA2141212C Defective adenovirus and corresponding complementation lines
04/17/2007CA2130803C Novel aminosterol antibiotic
04/17/2007CA2128486C Compositions comprising leucine, isoleucine, valine or mixtures thereof for use in the treatment of tardive dyskinesia
04/17/2007CA2124260C Tetrahydropyran derivatives
04/17/2007CA2106882C Azaquinoxalines, processes for their preparation and their use
04/17/2007CA2106819C Oligoribonucleotide and ribozyme analogs with terminal 3'-3' and/or 5'-5' linkages
04/17/2007CA1341525C Biologically active bactericidal/permeability-increasing protein fragments
04/14/2007CA2564064A1 Genetic variations associated with psychiatric disorders
04/14/2007CA2523399A1 Genetic variations associated with psychiatric disorders
04/13/2007CA2563496A1 Nicotine transdermal preparation and production method thereof
04/12/2007WO2007046971A2 Antiepileptogenic complex of albumin with docosahexaenoate
04/12/2007WO2007041719A2 Combination therapy using budesonide and antisense oligonucleotide targeted to il4-receptor alpha
04/12/2007WO2007041712A1 Pyrazolopyrimidines as protein kinase inhibitors
04/12/2007WO2007041681A2 Methods for treating respiratory disorders
04/12/2007WO2007041634A1 Pyrimidine amide compounds as pgds inhibitors
04/12/2007WO2007041630A1 Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
04/12/2007WO2007041616A1 Piperazine amidines as antiviral agents
04/12/2007WO2007041569A1 Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
04/12/2007WO2007041564A2 (s)-6-methyloxaalkyl exemestane compounds and related methods of use
04/12/2007WO2007041524A2 Novel parenteral carbamazepine formulation
04/12/2007WO2007041506A1 Purine formulations and methods for managing disorders
04/12/2007WO2007041499A2 Cox inhibitor and nicotinic acid compositions and methods
04/12/2007WO2007041495A2 Dampening humoral and innate immunity by inhibition of ppgalnact-1
04/12/2007WO2007041494A2 Cholesteryl ester transfer protein inhibitors
04/12/2007WO2007041479A2 Pharmaceutical compositions
04/12/2007WO2007041409A1 Pharmaceutical compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
04/12/2007WO2007041398A2 Treatment of cancer with specific rxr agonists
04/12/2007WO2007041379A1 Met kinase inhibitors
04/12/2007WO2007041368A2 Dpp iv inhibitor for use in the treatment of autoimmune diseases and graft rejection
04/12/2007WO2007041366A1 Sulfonamide derivatives as glycokinase activators useful in the treatment of type 2 diabetes
04/12/2007WO2007041362A1 2-amino-7,8-dihydro-6h-pyrido[4,3-d] pyrimidin-5-ones
04/12/2007WO2007041358A2 Substituted pyrazole compounds
04/12/2007WO2007041357A1 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
04/12/2007WO2007041341A2 Identification of anti-cancer compounds and compounds for treating huntington's disease and methods of treatment thereof
04/12/2007WO2007041324A1 Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
04/12/2007WO2007041294A2 Methods for sensitizing cancer cells to inhibitors
04/12/2007WO2007041283A2 Maternal chelation for embryo, fetal, and infant benefit
04/12/2007WO2007041270A1 Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by vla-4
04/12/2007WO2007041258A1 Benzothiadiazolyphenylalkylamine derivatives for use in the treatment of conditions ameliorated by monoamine reuptake
04/12/2007WO2007041230A2 Stable ascorbic acid compositions
04/12/2007WO2007041206A2 Drug delivery nanocarriers targeted by landscape phage
04/12/2007WO2007041195A2 Macroheterocylic compounds as kinase inhibitors
04/12/2007WO2007041156A2 Antibiotic formulations, unit doses, kits, and methods
04/12/2007WO2007041130A2 Deazapurines useful as inhibitors of janus kinases
04/12/2007WO2007041077A2 Heterocyclic amide derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes
04/12/2007WO2007041076A2 1,2,3,5-tetrahydro-cyclopental[c]quinolin-4-one derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes
04/12/2007WO2007041061A2 Acylated piperidine derivatives as melanocortin-4 receptor agonists
04/12/2007WO2007041052A2 Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
04/12/2007WO2007041023A1 1- (1h- indol- 1-yl) -3- (methylamino) -1- phenylpropan-2-ol derivatives and related compounds as modulators of the monoamine reuptake for the treatment of vasomotor symptoms (vms)
04/12/2007WO2007040982A1 5- (phenylisoxazolylethoxy) -triazol- 3 -yl substituted pyridine compounds for the treatment of neurological, psychiatric or pain disorders
04/12/2007WO2007040966A1 Normalization or remission of microalbuminuria
04/12/2007WO2007040711A2 Pharmaceutical formulations
04/12/2007WO2007040682A1 Biaryl substituted heterocycle inhibitors of lta4h for treating inflammation
04/12/2007WO2007040650A2 Apoptosis promoters
04/12/2007WO2007040591A2 A ubiquinone composition and a container for its convenient transport and storage
04/12/2007WO2007040565A2 Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
04/12/2007WO2007040535A1 Use of polyamine analogs for treatment and prevention of intestinal polyps
04/12/2007WO2007040529A1 Storage system for texaphyrin pharmaceutical formulations
04/12/2007WO2007040516A1 Novel cyclohexene carboamides and carbothioamides
04/12/2007WO2007040511A1 Stable combinations of amlodipine besylate and benazepril hydrochloride
04/12/2007WO2007040474A1 Novel polymorphs of (s)-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole monotartrate and methods of producing and using the same
04/12/2007WO2007040440A1 New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer’s disease
04/12/2007WO2007040439A1 New compounds ii
04/12/2007WO2007040438A2 Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders